MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas

B Oldrini, N Vaquero-Siguero, Q Mu, P Kroon… - Nature …, 2020 - nature.com
Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and
is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade …

Identifying predictors of glioma evolution from longitudinal sequencing

Q Mu, R Chai, B Pang, Y Yang, H Liu, Z Zhao… - Science translational …, 2023 - science.org
Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have
revealed divergent longitudinal trajectories in gliomas, but early molecular features steering …

[PDF][PDF] MYC amplification at diagnosis drives therapy-induced hypermutation of recurrent glioma

Q Mu, R Chai, H Liu, Y Yang, Z Zhao, MH Lui… - …, 2021 - scholar.archive.org
Abstract 1 Clonal evolution drives cancer progression and therapeutic resistance1, 2.
Recent 2 longitudinal analyses revealed divergent clonal dynamics in adult diffuse gliomas3 …

MYC amplification at diagnosis drives therapy-induced hypermutation of recurrent glioma

J Wang, Q Mu, R Chai, H Liu, Y Yang, Z Zhao, MH Lui… - 2021 - researchsquare.com
Clonal evolution drives cancer progression and therapeutic resistance 1-2. Recent
longitudinal analyses revealed divergent clonal dynamics in adult diffuse gliomas 3–11 …

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.

N Vaquero-Siguero, Q Mu, P Kroon, Y Zhang… - 2020 - repisalud.isciii.es
Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and
is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade …

[HTML][HTML] Genetic and microenvironmental evolution of colorectal liver metastases under chemotherapy

M Shi, Y Yang, N Huang, D Zeng, Z Mo, J Wang… - Cell Reports …, 2024 - cell.com
Drug resistance limits the efficacy of chemotherapy for colorectal cancer liver metastasis
(CRLM). However, the evolution of CRLM during drug treatment remains poorly elucidated …